Huiyu Pharmaceutical announced that the company recently received a “Drug Registration Certificate” for the company's product nicardipine hydrochloride injection approved and issued by the State Drug Administration. The drug is registered and classified as a chemical drug in 4 categories. After approval, it is treated as if it has passed the consistent evaluation of the quality and efficacy of generic drugs. Nicardipine hydrochloride injection is clinically used for emergency treatment of abnormal hypertension during surgery and emergency cases of hypertension. According to data from the Mi Intranet, sales of nicardipine hydrochloride injections in urban public hospitals in China in the first half of 2025 were about 306 million yuan. The company has carried out preliminary preparations for product launch and sales, but there is great uncertainty about whether it can generate large revenue in the future. Obtaining product registration approval will not have a significant impact on the company's business performance in the short term.

Huiyu Pharmaceutical announced that the company recently received a “Drug Registration Certificate” for the company's product nicardipine hydrochloride injection approved and issued by the State Drug Administration. The drug is registered and classified as a chemical drug in 4 categories. After approval, it is treated as if it has passed the consistent evaluation of the quality and efficacy of generic drugs. Nicardipine hydrochloride injection is clinically used for emergency treatment of abnormal hypertension during surgery and emergency cases of hypertension. According to data from the Mi Intranet, sales of nicardipine hydrochloride injections in urban public hospitals in China in the first half of 2025 were about 306 million yuan. The company has carried out preliminary preparations for product launch and sales, but there is great uncertainty about whether it can generate large revenue in the future. Obtaining product registration approval will not have a significant impact on the company's business performance in the short term.